Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Medtronic
McKesson
Dow
Johnson and Johnson

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR PROTONIX IV


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Protonix Iv

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00133770 ↗ Intravenous (IV) Pantoprazole in Erosive Esophagitis Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 4 2004-07-01 The aim of this study is to examine whether pantoprazole (Protonix) given through continuous intravenous infusion for 72 hours is superior to Protonix given through once a day IV injection in the treatment of erosive esophagitis.
NCT00133770 ↗ Intravenous (IV) Pantoprazole in Erosive Esophagitis Completed Emory University Phase 4 2004-07-01 The aim of this study is to examine whether pantoprazole (Protonix) given through continuous intravenous infusion for 72 hours is superior to Protonix given through once a day IV injection in the treatment of erosive esophagitis.
NCT00206050 ↗ Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po Completed AstraZeneca Phase 4 2004-09-01 This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole (NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ® Delayed Release Tablets ), in subjects who continue to require acid-suppressive therapy following a course of intravenous (iv) pantoprazole (PROTONIX ® I.V. for Injection).
NCT00625274 ↗ A Randomized, Open-Label, Comparative 3-Way Treatment Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40mg, Lansoprazole 30mg, and Pantoprazole 40mg at Steady State in NSAID-Using Patients Completed AstraZeneca Phase 4 2004-06-01 This study looks at controlling intragastric pH following administration of esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg taken orally, once daily in patients taking either non-selective or cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drugs (NSAIDs).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Protonix Iv

Condition Name

Condition Name for Protonix Iv
Intervention Trials
Healthy 10
Proton Pump Inhibitor Allergy 2
Healthy Adults 2
Esophagitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Protonix Iv
Intervention Trials
Gastroesophageal Reflux 5
Malnutrition 3
Psychotic Disorders 2
Mental Disorders 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Protonix Iv

Trials by Country

Trials by Country for Protonix Iv
Location Trials
United States 21
Canada 9
India 6
Puerto Rico 1
Germany 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Protonix Iv
Location Trials
Missouri 4
Texas 3
Wisconsin 2
California 2
Nebraska 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Protonix Iv

Clinical Trial Phase

Clinical Trial Phase for Protonix Iv
Clinical Trial Phase Trials
Phase 4 7
Phase 3 3
Phase 2/Phase 3 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Protonix Iv
Clinical Trial Phase Trials
Completed 20
Withdrawn 3
Terminated 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Protonix Iv

Sponsor Name

Sponsor Name for Protonix Iv
Sponsor Trials
Assiut University 2
Wyeth is now a wholly owned subsidiary of Pfizer 2
Mirati Therapeutics Inc. 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Protonix Iv
Sponsor Trials
Industry 22
Other 20
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Colorcon
Mallinckrodt
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.